Annai veilankanni’s college of pharmacy

Join WhatsApp Channel 

Crack GPAT — Prepare for GPAT Online 
  • PharmaTutor
    22 November 2012

    FORMULATION AND EVALUATION OF CINITAPRIDE TABLETS AS FLOATING DRUG DELIVERY SYSTEM

    About Authors:
    S.Dinesh*, M.Senthil Kumar, Ashok kumar, Hariharan, jenish, Marshal joseph
    Annai veilankanni’s pharmacy college
    saidapet, chennai – 600 015.
    Tamil nadu, pin:600015
    *dinesh.pharmacy@gmail.com

    ABSTRACT
    Cinitapride1-2, chemically4-amino-N[3-(Cyclohexan-1-yl-methyl)-4-piperidinyl]-2-ethoxy-5-nitrobenzamide has the molecular formula C21H30N4O4 and molecular weight 402.49 g.Cinitapride is a drug that has against action to the serotoninergic 5-HT2 and D2 dopaminergic receptors that has been indicated in the gastro esophageal reflux and in the functional disorders of gastrointestinal motility treatment, The present study was aimed to formulate and evaluvate the tablets containing Cinitapride based on floating  technique in order to increase gastric retention time, Total 9 formulation (F1-F9)were done using 3 different polymers like (HPMC k4m, HPMC e15m and HPMC k100m ). The formulations prepared were subjected to dissolution tests for 12 hrs, Among all the 9 formulation  formulation (F5) were able to efficiently control Cinitapride release over a time period of 12 hrs. Thus the results of the current study clearly indicate, a promising potential of the floating tablet as an alternative to conventional dosage form.

  • 21 November 2012
    FORMULATION AND EVALUATION OF FLOATING TABLETS USING ALFUZOSIN HYDROCHLORIDE AS A MODEL DRUG

    About Authors:
    Jenish.R*, M.Senthil kumar, Dinesh, Ahokkumar, Marshel, Hariharan
    Annai veilankanni’s college of pharmacy
    Saidapet, Chennai-600015
    Tamilnadu
    *jenishnathan@gmail.com

    ABSTRACT
    Alfuzosin is a non-subtype specific alpha(1)-adrenergic blocking agent that exhibits selectivity for alpha(1)-adrenergic receptors in the lower urinary tract. Inhibition of these adrenoreceptors leads to the relaxation of smooth muscle in the bladder neck and prostate, resulting in the improvement in urine flow and a reduction in symptoms in benign prostate hyperplasia. Alfuzosin also inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation. The alfuzosin of the present investigation is designed to retain in the stomach and deliver the drug alfuzosin for longer periods of time. The developed floating provides increased absorption of the alfuzosin at a rate such that effective plasma levels can be achieved and maintained for a prolonged duration. Formulations 6 displayed drug release considered in 0.1N HCL and Formulation 6 shows better drug release in dissolution profile.

  • 5 November 2012
    PREPARATION OF VILOXAZINE SUSTAINED RELEASE DRUG DELIVERY SYSTEM BY USING ETHYLCELLULOSE, CARBOPOL, SODIUM ALGINATE, HYDROXY PROPYL METHYL CELLULOSE & GUAR GUM

    About Authors:
    D. HariHaran*, M. Senthil kumar, M. Ashok Kumar, S. Dinesh & R.Jenish.
    Annai Veilankanni’s College of Pharmacy,
    81, V.G.P. Salai, Saidapet, Chennai-600015.
    *haran_pharma@yahoo.com

    ABSTRACT
    The present study behind this work is to find to prepare sustained release tablets of Viloxazine by compression method. First of all to formulate Viloxazine sustained release tablets using the Ethylcellulose, Carbopol, Sodium Alginate, Hydroxy propyl methyl cellulose & Guar gum under ratio’s  like 1:1, 1:1, 1:1,1:1,1:1 . Five batches were made in various polymers of ethylcellulose, carbopol, sodium alginate,hydroxy propyl methyl cellulose & guar gum is used by keeping the drug as constant. Then evaluation of Viloxazine sustained release tablets was carried out for characteristics like drug content in tablet, UV analysis. In vitro release starts from 1hr and up to 24hrs. It shows the percentage of gradual drug release as 17.80%, 27.65%, 35.12%, 45.16%, 51.20%, 57.42%, 61.30%, 66.32%, 72.08%, 77.15%, 81.32%, 84.48% & 98.20% against the label claim as 40mg.

  • 21 October 2012
    FORMULATION AND INVITRO EVALUATION OF IMMEDIATE RELEASE FOR QUETIAPINE FUMARATE IN TABLET DOSAGE FORM

    About Authors:
    Ashokkumar.m*, M.Senthil kumar, Dinesh, Jenish, Marshel, Hariharan
    Annai veilankanni’s college of pharmacy
    Saidapet, Chennai-600015, Tamilnadu
    *mgashokkumar123@gmail.com

    ABSTRACT
    Atypical antipsychotic Quetiapine was used for the treatment of schizophrenia is a severe illness with substantial effects on individual and social functioning, Quetiapine and its active metabolite N-desalkyl-Quetiapine have affinities to dopaminergic D1-and D2receptors,5-HT2 receptors. To design of immediate release dosage form of quetiapine fumarate that will help in releasing drug with short period of time. The quetiapine fumarate tablets were successfully prepared by direct compression method. The physiochemical evaluation results for the powdered material of all trials pass the official limits in angle of repose, compressibility index and drug content. In the 9 trials, the optimized formulation was F3 trial which releases the quetiapine fumarate  immediately within an hour.

Subscribe to Annai veilankanni’s college of pharmacy